94 related articles for article (PubMed ID: 26898077)
21. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
22. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
23. Expression of the c-kit proto-oncogene in myeloproliferative disorders and myelodysplastic syndromes.
Siitonen T; Savolainen ER; Koistinen P
Leukemia; 1994 Apr; 8(4):631-7. PubMed ID: 7512174
[TBL] [Abstract][Full Text] [Related]
24. FOXP1 molecular cytogenetics and protein expression analyses in primary cutaneous large B cell lymphoma, leg-type.
Espinet B; García-Herrera A; Gallardo F; Baró C; Salgado R; Servitje O; Estrach T; Colomo L; Romagosa V; Barranco C; Serrano S; Campo E; Pujol RM; Solé F
Histol Histopathol; 2011 Feb; 26(2):213-21. PubMed ID: 21154235
[TBL] [Abstract][Full Text] [Related]
25. MALT1, BCL10 and FOXP1 in salivary gland mucosa-associated lymphoid tissue lymphomas.
Borovecki A; Korac P; Ventura RA; Perisa MM; Banham AH; Dominis M
Pathol Int; 2007 Jan; 57(1):47-51. PubMed ID: 17199743
[TBL] [Abstract][Full Text] [Related]
26. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
27. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
28. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.
Medinger M; Tzankov A; Kern J; Pircher A; Hermann M; Ott HW; Gastl G; Untergasser G; Gunsilius E
Thromb Haemost; 2011 Jan; 105(1):72-80. PubMed ID: 20978717
[TBL] [Abstract][Full Text] [Related]
29. Both FOXP1 and p65 expression are adverse risk factors in diffuse large B-cell lymphoma: a retrospective study in China.
Hu CR; Wang JH; Wang R; Sun Q; Chen LB
Acta Histochem; 2013 Mar; 115(2):137-43. PubMed ID: 22809882
[TBL] [Abstract][Full Text] [Related]
30. [Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].
Tovar-Bobadilla JL; Ortiz-Hidalgo C
Gac Med Mex; 2016; 152(3):407-18. PubMed ID: 27335198
[TBL] [Abstract][Full Text] [Related]
31. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
Greenberg PL
Clin Haematol; 1986 Nov; 15(4):973-93. PubMed ID: 3552351
[No Abstract] [Full Text] [Related]
32. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
[TBL] [Abstract][Full Text] [Related]
33. [Expression of FOXP1 and cyclinE in primary central nervous system lymphoma and its significance].
Shen L; Chen BB; Chen Z; Xu XP; Lin GW
Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):648-52. PubMed ID: 23134861
[TBL] [Abstract][Full Text] [Related]
34. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
35. FOXP1 expression in monoclonal gammopathy of undetermined significance and multiple myeloma.
Korać P; Peran I; Skrtić A; Ajduković R; Kristo DR; Dominis M
Pathol Int; 2009 May; 59(5):354-8. PubMed ID: 19432679
[TBL] [Abstract][Full Text] [Related]
36. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
Bock O
Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
[TBL] [Abstract][Full Text] [Related]
37. Stage- and lineage-specific expression of the HOXA10 homeobox gene in normal and leukemic hematopoietic cells.
Lawrence HJ; Sauvageau G; Ahmadi N; Lopez AR; LeBeau MM; Link M; Humphries K; Largman C
Exp Hematol; 1995 Oct; 23(11):1160-6. PubMed ID: 7556525
[TBL] [Abstract][Full Text] [Related]
38. FOXP1 is a regulator of quiescence in healthy human CD4
Garaud S; Roufosse F; De Silva P; Gu-Trantien C; Lodewyckx JN; Duvillier H; Dedeurwaerder S; Bizet M; Defrance M; Fuks F; Bex F; Willard-Gallo K
Eur J Immunol; 2017 Jan; 47(1):168-179. PubMed ID: 27861791
[TBL] [Abstract][Full Text] [Related]
39. Serglycin proteoglycan in hematologic malignancies: a marker of acute myeloid leukemia.
Niemann CU; Kjeldsen L; Ralfkiaer E; Jensen MK; Borregaard N
Leukemia; 2007 Dec; 21(12):2406-10. PubMed ID: 17928883
[TBL] [Abstract][Full Text] [Related]
40. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p.
Banham AH; Beasley N; Campo E; Fernandez PL; Fidler C; Gatter K; Jones M; Mason DY; Prime JE; Trougouboff P; Wood K; Cordell JL
Cancer Res; 2001 Dec; 61(24):8820-9. PubMed ID: 11751404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]